HK Stock Market Move | INGDAN(00400) jumped nearly 8% in early trading, strategic upgrade to vertical AI Token factory operator, has signed over 1 billion US dollars in intent orders.
Yingtan Innovation (00400) rose nearly 8% in the morning session, as of the time of writing, it has risen by 6.16%, to 4.48 Hong Kong dollars, with a turnover of 13.83 million Hong Kong dollars.
INGDAN(00400) rose nearly 8% in early trading, as of press time, it has risen by 6.16% to HKD 4.48, with a turnover of HKD 13.8333 million.
On the news front, INGDAN released a voluntary announcement, announcing that the group has completed a strategic upgrade: transitioning from a distributor of artificial intelligence hardware to a vertical AIToken factory operator. Currently, it has accumulated signed intention service orders totaling over $1 billion, with clients including leading global cloud service providers, intelligent enterprises, and AI model manufacturers.
The company also disclosed that the group has established a vertical industry Token computing power scheduling platform, which will adopt a profit-sharing model for Token computing power, and lay out computing power infrastructure in a "dual-track model" with both self-owned computing power clusters and domestic and foreign third-party computing power centers. The board of directors believes that the group has established a first-mover advantage in the vertical AI computing power track and will continue to expand distributed computing power nodes, iterate industry-specific Token products, and develop Token operation services into the group's second growth curve.
Related Articles

JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).
.png)
UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
JENSCARE-B(09877): The first group of subjects implanted with the LuX-ValvePlus transcatheter tricuspid valve replacement system have completed the key pivotal trial approved by the FDA.

SSY GROUP (02005): Procured drug production registration certificate for Fenobet Acid Choline Sustained-Release Capsules (135mg).

UNITED LAB (03933) received a milestone payment of $13.5 million from Novonordisk for the exclusive licensing agreement for UBT251.
.png)
RECOMMEND





